BibbInstruments

BibbInstruments Forward P/E

The Forward P/E Ratio of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is -4.74. In the previous year, Forward P/E Ratio was -5.45 — a change of -13.02% (higher).

Forward P/E

-4.74

YoY

-13.02%

Last updated:

Forward P/E Ratio of BibbInstruments is 2025 -4.74 . Forward P/E Ratio of BibbInstruments was 2024 -5.45 . It decreases by -13.02% higher compared to the previous year.

The BibbInstruments Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-8.95 SEK
Jan 1, 2019
-4.55 SEK
Jan 1, 2020
-5.44 SEK
Jan 1, 2021
-6.75 SEK
Jan 1, 2022
-6.15 SEK
Jan 1, 2023
-6.32 SEK
Jan 1, 2024
-5.45 SEK
Jan 1, 2025
-4.74 SEK
The BibbInstruments Forward P/E history
YEARForward P/EYoY
-4.74-13.02%
-5.45-13.68%
-6.32+2.80%
-6.15-8.91%
-6.75+24.08%
-5.44+19.46%
-4.55-49.11%
-8.95-48.31%
-17.31-100.02%
99,028.57+114.29%
46,213.33+926.67%
4,501.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Forward P/E Ratio of BibbInstruments is -4.74 in 2025.

Forward P/E Ratio of BibbInstruments changed from -5.45 to -4.74, representing a -13.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's BibbInstruments with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BibbInstruments

All Key Metrics — BibbInstruments